Search Results - "Gatey, Caroline"

COVID‐19–Related IgA Vasculitis by Allez, Matthieu, Denis, Blandine, Bouaziz, Jean‐David, Battistella, Maxime, Zagdanski, Anne‐Marie, Bayart, Jules, Lazaridou, Ingrid, Gatey, Caroline, Pillebout, Evangeline, Chaix Baudier, Marie‐Laure, Delaugerre, Constance, Molina, Jean‐Michel, Le Goff, Jérôme

Get full text

Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial by Lafaurie, Matthieu, Chevret, Sylvie, Fontaine, Jean-Paul, Mongiat-Artus, Pierre, de Lastours, Victoire, Escaut, Lélia, Jaureguiberry, Stéphane, Bernard, Louis, Bruyere, Franck, Gatey, Caroline, Abgrall, Sophie, Ferreyra, Milagros, Aumaitre, Hugues, Aparicio, Caroline, Garrait, Valérie, Meyssonnier, Vanina, Bourgarit-Durand, Anne, Chabrol, Amélie, Piet, Emilie, Talarmin, Jean-Philippe, Morrier, Marine, Canoui, Etienne, Charlier, Caroline, Etienne, Manuel, Pacanowski, Jerome, Grall, Nathalie, Desseaux, Kristell, Empana-Barat, Florence, Madeleine, Isabelle, Bercot, Béatrice, Molina, Jean-Michel, Lefort, Agnès

“…Abstract Background The optimal duration of antimicrobial therapy for urinary tract infections (UTIs) in men remains controversial. Methods To compare 7 days…”
Get full text

Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance by Lambert-Niclot, Sidonie, Abdi, Basma, Bellet, Jonathan, Fofana, Djeneba, De Truchis, Pierre, Amat, Karine, Alvarez, Jean-Claude, Surgers, Laure, Allavena, Clothilde, Zaegell-Faucher, Olivia, Morlat, Philippe, Palich, Romain, Gibowski, Séverine, Costagliola, Dominique, Girard, Pierre-Marie, Landman, Roland, Assoumou, Lambert, Morand-Joubert, Laurence

“…Abstract Background In a 4 days/week (4/7 days) maintenance strategy (ANRS-170 QUATUOR trial), the virological impact of an intermittent strategy was assessed…”
Get full text

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study by Orrell, Catherine, Hagins, Debbie P, Belonosova, Elena, Porteiro, Norma, Walmsley, Sharon, Falcó, Vicenç, Man, Choy Y, Aylott, Alicia, Buchanan, Ann M, Vavro, Cindy, Aboud, Michael, Smith, Kimberly Y, Cahn, Pedro Enrique, Cassetti, Lidia Isabel, Porteiro Barreira, Norma, Angel, Jonathan Benjamin, de Pokomandy, Alexandra, Harris, Marianne, Rachlis, Anita R., Walmsley, Sharon L., Bouchaud, Oliver, Gatey, Caroline, Rami, Agathe, Casari, Salvatore, Di Perri, Giovanni, Lazzarin, Adriano, Maggiolo, Franco, Penco, Giovanni, Quirino, Tiziana, Rizzardini, Giuliano, Andrade-Villanueva, Jaime-Federico, Sierra-Madero, Juan G., Branco, Teresa, Serrao, Rosario, Teofilo, Eugenio JR, Melendez-Rivera, Ivan, Santiago, Lizette, Zorrilla, Carmen D., Belonosova, Elena, Chernova, Oksana E., Pokrovsky, Vadim, Rakhmanova, Aza Gasanovna, Voronin, Eugene, Orrell, Catherine, Vally, Tasneem, Farisani, Livhuwani ML, Barros, Carlos Aguado, Cano Sánchez, Alfredo, Castaño, Manuel, Falcó Ferrer, Vicens, González García, Juan J., Hernandez-Quero, Jose, Negredo Puigmal, Eugenia, Pérez Elías, María Jesús, Podzamczer Palter, Daniel, Portilla, Joaquin Sogorb, Viciana Fernández, Pompeyo, Manosuthi, Weerawat, Ruxrungtham, Kiat, Dockrell, David H., Hay, Phillip E., Johnson, Margaret A., Mackie, Nicola E., Orkin, Chloe M., Taylor, Steve, Bhatti, Laveeza, Brar, Indira, Brennan, Robert Owen, Cade, Jerry L., Casanas, Beata, Casey, Kathleen, Cunningham, Douglas, DeJesus, Edwin, Dietz, Craig, Dretler, Robin Henry, Eron, Joseph J., Felizarta, Franco Antoni B., Fife, Kenneth H., Hagins, Debbie P., Hoffman-Terry, Margaret, Jain, Mamta, Johnson, Marc Alexander, Kinder, Clifford A., Kumar, Princy N., Lewis, Stanley T., McDonald, Cheryl Kay, Meza, Armando D., Mounzer, Karam C., Newman, Cheryl L., Poblete, Ronald, Ramgopal, Moti, Rosenstock, Joel, Samuel, Rafik, Sandkovsky, Uriel Sebastian, Shon, Alyssa So Young, Skiest, Daniel J., Sloan, Louis M., Small, Catherine B., Tebas, Pablo, Van Dam, Cornelius N.

“…Dolutegravir is a once-daily integrase strand transfer inhibitor with no need for pharmacokinetic boosting that is approved for the treatment of HIV-1…”
Get full text

A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial by Landman, Roland, de Truchis, Pierre, Assoumou, Lambert, Lambert, Sidonie, Bellet, Jonathan, Amat, Karine, Lefebvre, Bénédicte, Allavena, Clotilde, Katlama, Christine, Yazdanpanah, Yazdan, Molina, Jean-Michel, Gibowski, Séverine, Alvarez, Jean-Claude, Leibowitch, Jacques, Capeau, Jacqueline, Fellahi, Soraya, Girard, Pierre-Marie, FORCE, Gilles, CABY, Fabienne, PATEY, Olivier, FRESARD, Anne, CHIROUZE, Catherine, DUVIVIER, Claudine, LOURENCO, Jérémie, LEROLLE, Nathalie, CATALAN, Pilartxo, RAMI, Agathe, DE PONTHAUD, Lucile, PICHANCOURT, Gilles, NASRI, Safa, LANDOWSKI, Stéphanie, BOTTERO, Julie, PIALOUX, Gilles, BOUCHAUD, Olivier, GATEY, Caroline, WEISS, Laurence, PAVIE, Juliette, SALMON-CERON, Dominique, ZUCMAN, David, PALICH, Romain, SIMON, Anne, MEYOHAS, Marie-Caroline, GRAS, Julien, CABIE, André, MORLAT, Philippe, HESSAMFAR, Mojgam, NEAU, Didier, CAZENAVE, Charles, GENET, Claire, FAUCHER, Jean-François, MAKHLOUFI, Djamila, BOIBIEUX, André, BREGIGEON-RONOT, Sylvie, LAROCHE, Hélène, SAUTEREAU, Aurélie, REYNES, Jacques, MAKINSON, Alain, BOLLENGIER-STRAGIER, Olivier, NAQVI, Alissa, CUA, Eric, ROSENTHAL, Eric, REY, David, BERNARD, Louis, DELOBEL, Pierre, PIFFAUT, Marie, VERDON, Renaud, PIROTH, Lionel, BLOT, Mathieu, LECLERCQ, Pascale, HULEUX, Thomas, MAY, Thierry, MIAILHES, Patrick, GREDER-BELAN, Alix, MICHAU, Christophe, PRAZUCK, Thierry, PHILIBERT, Patrick, SLAMA, Laurence, HIKOMBO, Hitoto, DARASTEANU, Iuliana, ALVAREZ, Jean-Claude, MATHEZ, Dominique, DE TRUCHIS, Pierre, LANDMAN, Roland, MEYNARD, Jean-Luc, MORAND-JOUBERT, Laurence, LAMBERT, Sidonie, LE DU, Damien, ASSOUMOU, Lambert, COSTAGLIOLA, Dominique, MELCHIOR, Jean-Claude, DURACINSKI, Martin, PETROV-SANCHEZ, Ventzislava, AMAT, Karine, GELLEY, Ambre, GIBOWSKI, Séverine, LE MEUT, Guillaume, THIEBAUT, Rodolphe, CLUMECK, Nathan, LECLERCQ, Vincent, DECOSTER, Laurent

“…Intermittent (on 4 days per week) antiretroviral therapy (ART) for patients with HIV-1 might be more convenient, better tolerated, and cheaper than continuous…”
Get full text

Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study by Gazaignes, Sandrine, Resche-Rigon, Matthieu, Gatey, Caroline, Yang, Chloe, Denis, Blandine, Fonsart, Julien, Desseaux, Kristell, Guionie, Michel, Rozenbaum, Willy, Delaugerre, Constance, Molina, Jean-Michel

“…Rilpivirine (RPV) is a second-generation once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI) which has shown non-inferior antiviral activity to…”
Get more information

Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? by Molina, Jean-Michel, Pintado, Claire, Gatey, Caroline, Ponscarme, Diane, Charbonneau, Pierre, Loze, Benedicte, Rozenbaum, Willy, Delaugerre, Constance

“…Following US Food and Drugs Administration approval in July 2012 of daily oral tenofovir and emtricitabine for pre-exposure prophylaxis (PrEP) to prevent HIV…”
Get full text

La prévention pré-exposition au VIH-1 par les antirétroviraux, la PrEP by Delaugerre, Constance, Gatey, Caroline, Chaix, Marie-Laure, Molina, Jean-Michel

Get full text

Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients by Pradat, Pierre, Durant, Jacques, Brochier, Corinne, Trabaud, Mary-Anne, Cottalorda-Dufayard, Jacqueline, Izopet, Jacques, Raffi, François, Lucht, Frédéric, Gagnieu, Marie-Claude, Gatey, Caroline, Jacomet, Christine, Vassallo, Matteo, Dellamonica, Pierre, Cotte, Laurent

“…We assessed the virological efficacy of a 6 month maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy combining tenofovir…”
Get full text

Efficacy and safety of rilpivirine‐based regimens in treatment‐experienced HIV‐1 infected patients: a prospective cohort study by Gazaignes, Sandrine, Resche‐Rigon, Matthieu, Yang, Chloe, Gatey, Caroline, Munier, Anne‐Lise, Desseaux, Kristell, Rozenbaum, Willy, Molina, Jean‐Michel

“…Introduction Rilpivirine (RPV) is a new once‐daily, non‐nucleoside, reverse transcriptase inhibitor (NNRTI). In treatment‐naïve patients, RPV has shown…”
Get full text

Traitement pré-exposition en prévention du VIH par ténofovir disoproxil fumarate et emtricitabine by GATEY, Caroline, PINTADO, Claire, MOLINA, Jean-Michel

Get full text

COVID-19-Related IgA Vasculitis by Allez, Matthieu, Denis, Blandine, Bouaziz, Jean-David, Battistella, Maxime, Zagdanski, Anne-Marie, Bayart, Jules, Lazaridou, Ingrid, Gatey, Caroline, Pillebout, Evangeline, Chaix Baudier, Marie-Laure, Delaugerre, Constance, Molina, Jean-Michel, Le Goff, Jérôme

Get full text

Tuberculosis treatment in adults by Gatey, Caroline, Bouvet, Elisabeth

“…The quadritherapy by isoniazid, rifampicin, pyrazinamide and ethambutol, is still the gold standard for the treatment of tuberculosis disease. Except for…”
Get more information

Pre-exposure prophylaxis of HIV infection by Gatey, Caroline, Pintado, Claire, Chas, Julie, Pialouxr, Gilles, Molina, Jean-Michel

Get more information